Sarah Mary Carlton Colbert

Sarah Mary Carlton Colbert

Auto-generated profile, based on publicly available information

Sarah Mary Carlton Colbert

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Nature Mental Health
Verified
Journal Article
Closed access
PDF file
AHAlexander S. Hatoum
Alexander S. Hatoum
SCSarah M. C. Colbert
Sarah M. C. Colbert
EJEmma Johnson
Emma Johnson
SHSpencer B. Huggett
Spencer B. Huggett
JDJoseph D. Deak
Joseph D. Deak
AAArpana Agrawal
Arpana Agrawal

8 November 2021 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
AHAlexander S. Hatoum
Alexander S. Hatoum
EJEmma Johnson
Emma Johnson
SCSarah M. C. Colbert
Sarah M. C. Colbert
RPRenato Polimanti
Renato Polimanti
HZHang Zhou
Hang Zhou
AAArpana Agrawal
Arpana Agrawal

10 March 2022 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
DLDongbing Lai
Dongbing Lai
EJEmma Johnson
Emma Johnson
SCSarah Colbert
Sarah Colbert
GPGayathri Pandey
Gayathri Pandey
GCGrace Chan
Grace Chan
TFTatiana Foroud
Tatiana Foroud

25 November 2021 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
SCSarah M. C. Colbert
Sarah M. C. Colbert
AHAlexander S. Hatoum
Alexander S. Hatoum
ASAndrey Shabalin
Andrey Shabalin
QLQingqin S. Li
Qingqin S. Li
HCHilary Coon
Hilary Coon
EJEmma Johnson
Emma Johnson

4 July 2024 in Nature Mental Health
Verified
Journal Article
Closed access
PDF file
DBDavid A. A. Baranger
David A. A. Baranger
AMAlex P. Miller
Alex P. Miller
AGAaron J. Gorelik
Aaron J. Gorelik
SPSarah E. Paul
Sarah E. Paul
AHAlexander S. Hatoum
Alexander S. Hatoum
RBRyan Bogdan
Ryan Bogdan

21 June 2024 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
EJEmma Johnson
Emma Johnson
IAIsabelle Austin-Zimmerman
Isabelle Austin-Zimmerman
HTHayley H. A. Thorpe
Hayley H. A. Thorpe
DLDaniel F. Levey
Daniel F. Levey
DBDavid A. A. Baranger
David A. A. Baranger
AAArpana Agrawal
Arpana Agrawal
Individuals with schizophrenia frequently experience co-occurring substance use, including tobacco smoking and heavy cannabis use, and substance use disorders. There is interest in understanding the extent to which these relationships are causal, and to what extent shared genetic factors play a role. We explored the relationships between schizophrenia (Scz; European ancestry N = 161,405; African ancestry N = 15,846), cannabis use disorder (CanUD; European ancestry N = 886,025; African ancestry N = 120,208), and ever-regular tobacco smoking (Smk; European ancestry N = 805,431; African ancestry N = 24,278) using the largest available genome-wide studies of these phenotypes in individuals of African and European ancestries. All three phenotypes were positively genetically correlated (rgs = 0.17–0.62). Genetic instrumental variable analyses suggested the presence of shared heritable factors, but evidence for bidirectional causal relationships was also found between all three phenotypes even after correcting for these shared genetic factors. We identified 327 pleiotropic loci with 439 lead SNPs in the European ancestry data, 150 of which were novel (i.e., not genome-wide significant in the original studies). Of these pleiotropic loci, 202 had lead variants which showed convergent effects (i.e., same direction of effect) on Scz, CanUD, and Smk. Genetic variants convergent across all three phenotypes showed strong genetic correlations with risk-taking, executive function, and several mental health conditions. Our results suggest that both shared genetic factors and causal mechanisms may play a role in the relationship between CanUD, Smk, and Scz, but longitudinal, prospective studies are needed to confirm a causal relationship.